Features | Partner Sites | Information | LinkXpress
Sign In
GLOBETECH PUBLISHING LLC
PZ HTL SA
GLOBETECH PUBLISHING LLC

Peptide Mapping Columns Provide Faster, More Robust Performance

By BiotechDaily International staff writers
Posted on 21 May 2013
Image: The Agilent BioHPLC peptide mapping columns (Photo courtesy of Agilent Technologies).
Image: The Agilent BioHPLC peptide mapping columns (Photo courtesy of Agilent Technologies).
Image: The rapid resolution high definition Agilent ZORBAX RRHD 300-HILIC columns (Photo courtesy of Agilent Technologies).
Image: The rapid resolution high definition Agilent ZORBAX RRHD 300-HILIC columns (Photo courtesy of Agilent Technologies).
New high-performance peptide mapping-column solutions for HPLC and HILIC enable users to achieve results at exceptionally higher resolution and do it quicker.

Agilent Technologies Inc. (Santa Clara, CA, USA) has now introduced the latest upgrades to its “AdvancBio” family of columns for peptide mapping—the “BioHPLC” column and the “ZORBAX RRHD 300-HILIC” rapid resolution high definition for UHPLC column. These columns have been designed to deliver exceptional performance for the separation, characterization, and analysis of a wide range of proteins, monoclonal antibodies, peptides, and additional biologics. "We are excited to introduce these valuable new columns to our pharmaceutical customers and other life science researchers seeking ever-greater analytical sensitivity and speed," said Anne Jones, Agilent's vice president and general manager for the chemistries business. "These products are an example of our ongoing commitment to advancing accuracy and productivity in biochromatography."

The new AdvanceBio Peptide Mapping column can rapidly determine the primary protein structure and identify modifications with unparalleled speed and sensitivity. In fact, it can produce exceptional analytical results 2 to 3 times faster than conventional peptide mapping with fully porous HPLC columns, which can take up to 60 minutes. Each batch of AdvanceBio mapping media is tested with a rigorous peptide mix to ensure suitability and reproducibility, enabling the identification of key peptides in complex peptide maps. All available columns are stable to 600-bar, enabling maximum UHPLC instrument performance. They also deliver exceptional performance with legacy 400-bar instruments.

The AdvanceBio Peptide Mapping column is excellent for highly complex peptide mapping and will provide 100% sequence coverage of many protein digests, including rhEPO with 45 glycopeptide matches. These features are explored in the application note - High-Resolution Glycopeptide Mapping of EPO Using an Agilent AdvanceBio Peptide Mapping Column.

The ZORBAX RRHD 300-HILIC columns are the only sub 2-µm, 300Å HILIC columns available today. They are designed specifically for users seeking faster, higher-resolution separation of peptides, polar glycopeptides, proteins, antibodies, conjugates, new biological entities, and biopharmaceuticals. Hydrophilic interaction liquid chromatography is designed to resolve hydrophilic glycopeptide variants. It also provides excellent peak shape for polar glycopeptides that have limited retention and resolution with reversed-phased columns. For 1.8 µm particles, the ZORBAX RRHD 300-HILIC columns enable rapid analysis and 1200-bar stability with exceptional accuracy. They provide orthogonal and complementary separations to reversed-phase HPLC. These features are explored in the application note - Analysis of Erythropoietin Glycopeptides and Glycoforms by HILIC and RP Chromatography.

Related Links:

Agilent Technologies
AdvancBio Peptide Mapping Columns




comments powered by Disqus

Channels

Genomics/Proteomics

view channel
Image: This novel, flexible film that can react to light is a promising step toward an artificial retina (Photo courtesy of the American Chemical Society).

Novel Nanofilm May Be Artificial Retina Precursor

Researchers have used advanced nanotechnology techniques to develop a light-sensitive film that has potential for future artificial retina applications. Investigators at the Hebrew University of Jerusalem... Read more

Drug Discovery

view channel
Image: Disruption and removal of malaria parasites by the experimental drug (+)-SJ733 (Photo courtesy of the University of California, San Francisco).

Experimental Antimalaria Drug Induces the Immune System to Destroy Infected Red Blood Cells

An experimental drug for the treatment of malaria was found to induce morphological changes in infected erythrocytes that enabled the immune system to recognize and eliminate them. Investigators at... Read more

Biochemistry

view channel

Blocking Enzyme Switch Turns Off Tumor Growth in T-Cell Acute Lymphoblastic Leukemia

Researchers recently reported that blocking the action of an enzyme “switch” needed to activate tumor growth is emerging as a practical strategy for treating T-cell acute lymphoblastic leukemia. An estimated 25% of the 500 US adolescents and young adults diagnosed yearly with this aggressive disease fail to respond to... Read more

Business

view channel

R&D Partnership Initiated to Reduce Development Time for New Drugs

nanoPET Pharma, GmbH (Berlin, Germany) signed an open-ended framework contract with the international pharmaceutical company Boehringer Ingelheim (Ridgefield, CT, USA). By developing customized contrast agents for research in both basic and preclinical studies, nanoPET Pharma will contribute to the enhancement of Boehringer... Read more
 
Copyright © 2000-2014 Globetech Media. All rights reserved.